Literature DB >> 25448998

Uveitis in Behçet disease in a tertiary center over 25 years: the KKESH Uveitis Survey Study Group.

J Fernando Arevalo1, Andres F Lasave2, Mohanna Yousef Al Jindan3, Nasser Abdulmohsen Al Sabaani4, Ammar M Al-Mahmood3, Yahya A Al-Zahrani3, Hassan A Al Dhibi3.   

Abstract

PURPOSE: To describe the features of Behçet-associated uveitis over a 25-year period.
DESIGN: Retrospective observational case series.
METHODS: A chart review of patients with Behçet-associated uveitis who were evaluated from January 1986 to December 2011 at King Khaled Eye Specialist Hospital, Saudi Arabia. Demographic data, symptoms, type of uveitis, treatment, and complications were evaluated. The main outcome measures were presenting symptoms, types of uveitis, treatment, and complications.
RESULTS: There were 132 patients (232 eyes; 102 male [77.3%]) evaluated with age of onset of 36.9 ± 11.4 years. Panuveitis was the most common presentation, affecting 118 patients (89.4%). Episodes were bilateral in 100 patients (75.8%). Baseline best-corrected visual acuity (BCVA) was 20/125 in both eyes. Retinal vasculitis at presentation occurred in 61 eyes (26.3%), occlusive vasculitis in 59 eyes (25.4%), and macular edema in 42 eyes (18.1%). Common therapeutic management included oral corticosteroids in 123 patients (93.2%), intravenous steroid therapy in 35 patients (26.5%), cyclosporine in 98 patients (74.2%), and azathioprine in 65 patients (49.2%). Common anterior segment complications included glaucoma (44 eyes, 19%) and cataracts (34 eyes, 14.7%). The most common posterior segment complication was optic nerve atrophy. Cataract surgery was the most common surgery. At last visit, BCVA was better than 20/50 in 131 eyes (56.5%).
CONCLUSIONS: Behçet-associated uveitis predominantly affects young men in Saudi Arabia. Bilateral panuveitis associated with retinal vasculitis was the most common manifestation. More than 50% of patients maintained 20/50 or better BCVA at final follow-up and were primarily managed with oral corticosteroids and other immunosuppressive agents.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25448998     DOI: 10.1016/j.ajo.2014.10.013

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  7 in total

1.  Pattern and causes of visual loss in Behçet's uveitis: short-term and long-term outcomes.

Authors:  Radgonde Amer; Walaa Alsughayyar; Diego Almeida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-04-10       Impact factor: 3.117

Review 2.  Orbital Vasculitides-Differential Diagnosis.

Authors:  Gabriela M Espinoza; Jessica L Liu
Journal:  Curr Rheumatol Rep       Date:  2019-09-05       Impact factor: 4.592

3.  Purtscher-like retinopathy with macular ischemia as the initial presentation of Behcet's disease.

Authors:  Min Ho Shin; Woong Sun Yoo; Ji Sung Jung; In Young Chung
Journal:  Int J Ophthalmol       Date:  2022-03-18       Impact factor: 1.779

4.  Ciclosporin A in bilateral auto-immune chronic posterior uveitis associated with macular oedema: a Long-term Observational Safety and Efficacy Study.

Authors:  Munirah Alafaleq; Romain Freund; Marie-Aude Penet; Christine Fardeau; Corinne Isnard-Bagnis; Sophie Tezenas du Montcel; Gilbert Deray; Phuc LE Hoang; Bahram Bodaghi; Isabelle Tostivint
Journal:  Eye (Lond)       Date:  2021-10-30       Impact factor: 4.456

Review 5.  Retinal vasculitis.

Authors:  James T Rosenbaum; Cailin H Sibley; Phoebe Lin
Journal:  Curr Opin Rheumatol       Date:  2016-05       Impact factor: 5.006

6.  In vitro study of cyclosporine A 0.05 % on primary and recurrent pterygium fibroblasts.

Authors:  Magda Massae Hata Viveiros; Fabiano Yutaka Kakizaki; Laura Almeida Hércules; Carlos Roberto Padovani; João Manuel Grisi Candeias; Silvana Artioli Schellini
Journal:  Int Ophthalmol       Date:  2015-08-11       Impact factor: 2.031

7.  Choroidal Thickness Indicates Subclinical Ocular and Systemic Inflammation in Eyes with Behçet Disease without Active Inflammation.

Authors:  Yoo Ri Chung; Eun Hyung Cho; Seran Jang; Seung Yeop Lee; Eun So Lee; Kihwang Lee
Journal:  Korean J Ophthalmol       Date:  2018-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.